NGF and migraine disorder: Biological therapies like monoclonal antibodies (mAbs) against nerve growth factor (NGF) (e.g., tanezumab) and calcitonin gene-related peptide (CGRP) (e.g., erenumab) have shown promise in the treatment of chronic pain conditions such as osteoarthritis and migraines [14,15].